Ramón Bover Freire-rekin lankidetzan egindako argitalpenak (9)

2023

  1. Do Women Physicians Accept and Follow Heart Failure Guidelines More Than Men?

    Current Heart Failure Reports, Vol. 20, Núm. 3, pp. 151-156

  2. Ferric carboxymaltose for patients with heart failure in all-range ejection fraction

    REC: CardioClinics, Vol. 58, Núm. 4, pp. 281-288

  3. Opinion on the 2021 ESC guidelines on heart failure: a cross-sectional survey of 387 doctors

    REC: CardioClinics, Vol. 58, Núm. 1, pp. 7-15

2022

  1. Impact of blood pressure on management and prognosis of patients treated with sacubitril/valsartan

    REC: CardioClinics, Vol. 57, Núm. 2, pp. 116-122

2021

  1. Initiation and titration of sacubitril/valsartan in different types of centers

    REC: CardioClinics, Vol. 56, Núm. 2, pp. 92-97

  2. Predictors of clinical improvement in heart failure patients with iron deficiency treated with ferric carboxymaltose

    REC: CardioClinics, Vol. 56, Núm. 4, pp. 250-257

  3. Predictors of clinical improvement in heart failure patients with iron deficiency treated with ferric carboxymaltose

    REC: CardioClinics, Vol. 56, Núm. 4, pp. 250-257

2020

  1. Sacubitril/Valsartan is useful and safe in elderly people with heart failure and reduced ejection fraction. Data from a real-word cohort

    Revista Espanola de Geriatria y Gerontologia, Vol. 55, Núm. 2, pp. 65-69

2019

  1. Safety of sacubitril/valsartan initiated during hospitalization: data from a non-selected cohort

    ESC Heart Failure, Vol. 6, Núm. 6, pp. 1161-1166